LigaChem Biosciences Inc.

Equities

A141080

KR7141080002

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 13/05/2024 BST			5-day change	1st Jan Change
65,700 ^KRW	-1.20%		-3.95%	+1.08%

04-08	NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	CI
03-29	Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin.	CI

Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.

December 28, 2023 at 01:45 am

From October 1, 2023 to December 28, 2023, the company has repurchased 30,000 shares, representing 0.11% for KRW 1,013.01 million. With this, the company has completed the repurchase of 140,000 shares, representing 0.53% for KRW 4,879.08 million under the buyback announced on June 28, 2023.

Latest news about LigaChem Biosciences Inc.

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024	04-08	CI
Pan Orion Corp. Ltd. completed the acquisition of 4.93% stake in LegoChem Biosciences, Inc. from Kim Yong Ju and Park Se Jin.	03-28	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Samsung Biologics Collaborates with LegoChem Biosciences on ADC Development and Manufacturing	02-09	MT
Orion Set to Acquire 25% Stake in LegoChem Biosciences	01-17	MT
South Korean Shares Close Lower Amid Geopolitical Tension	01-16	MT
Legochem Biosciences to Raise 469.8 Billion Won through Rights Issue; Shares Fall 5%	01-16	MT
LegoChem Biosciences, Inc. announced that it expects to receive KRW 1018.327793998 billion in funding from Pan Orion Corp. Ltd.	01-14	CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	12-28	CI
LegoChem Biosciences, Inc.'s Equity Buyback announced on June 28, 2023, has expired with 140,000 shares, representing 0.53% for KRW 4,879.08 million.	12-27	CI
J&J: licensing agreement with Korea's LegoChem in ADCs	12-27	CF
Legochem Biosciences Announces License Agreement for Lcb84 Trop2-Targeted ADC	12-26	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
BostonGene and LegoChem Biosciences, Inc. Announce Collaboration to Support Phase I/II Study of LCB84, TROP2-Directed ADC, in Patients with Advanced Cancers	11-07	CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	04/10/23	CI
Tranche Update on LegoChem Biosciences, Inc.'s Equity Buyback Plan announced on June 28, 2023.	04/10/23	CI
Bridge Biotherapeutics, Inc. announced that it has received KRW 5.9999904 billion in funding from LegoChem Biosciences, Inc.	04/09/23	CI
Bridge Biotherapeutics, Inc. announced that it expects to receive KRW 5.9999904 billion in funding from LegoChem Biosciences, Inc.	27/08/23	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/08/23	CI
LegoChem Biosciences, Inc. announces an Equity Buyback for KRW 5,000 million worth of its shares.	28/06/23	CI
LegoChem Biosciences, Inc. authorizes a Buyback Plan.	27/06/23	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	15/05/23	CI
LegoChem Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23/03/23	CI
LegoChem Biosciences, Amgen in Licensing Agreement	23/12/22	DJ
Legochem Biosciences and Amgen Enter into A Multi-Target Research Collaboration and License Agreement for the Development of Antibody-Drug Conjugates	23/12/22	CI

Chart LigaChem Biosciences Inc.

Duration

Period

More charts

Company Profile

LigaChem Biosciences Inc, formerly LegoChem Biosciences Inc, is a Korea-based biotechnology company mainly engaged in development and discovery of new pharmaceuticals based on medical chemistry. The Company principally involves in the development of new drugs, including antibiotics, anticoagulants, anticancer, antiplatelet, anti-inflammatory, as well as antibody-drug-conjugates (ADC), among others. The Company provides technology transfer, joint and contact research and research services. In addition, the Company sells pharmaceutical products.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for LigaChem Biosciences Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
LIGACHEM BIOSCIENCES INC.	+1.08%	1.73B
VERTEX PHARMACEUTICALS INCORPORATED	+7.23%	111B
REGENERON PHARMACEUTICALS, INC.	+10.13%	106B
BIONTECH SE	-12.34%	22.24B
ARGENX SE	+0.44%	21.25B
GENMAB A/S	-4.18%	18.97B
WUXI APPTEC CO., LTD.	-37.85%	18.52B
BEIGENE, LTD.	-9.14%	16.81B
SAREPTA THERAPEUTICS, INC.	+37.92%	12.54B
LEGEND BIOTECH CORPORATION	-24.95%	8.09B

Bio Therapeutic Drugs